7 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
14 Mar 13
Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function In Patients with Cancer Published In the Lancet Oncology
12:00am
included assessments of the effects of enobosarm on total body weight, physical function, and quality of life. Baseline demographic (age, sex, race and BMI
8-K
EX-1.1
ONCT
Oncternal Therapeutics Inc
17 Dec 21
Entry into a Material Definitive Agreement
5:17pm
they were made, not misleading.
(f) Statistical and Market-Related Data. The statistical, demographic and market-related data included
8-K
EX-1.1
ONCT
Oncternal Therapeutics Inc
28 May 21
Entry into a Material Definitive Agreement
5:03pm
, not misleading.
(f) Statistical and Market-Related Data. The statistical, demographic and market-related data included in the Registration Statement
- Prev
- 1
- Next